Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Montanide adjuvant Clear all
Completed Phase 2 Interventional Results available

Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

NCT05243862
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
PolyPEPI1018, Atezolizumab
Drug
Lead sponsor
Treos Bio Limited
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 9:40 AM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

NCT00001703
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
incomplete Freund's adjuvant, von Hippel-Lindau peptide vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients

NCT01585350
View directory record Official record
Conditions
Melanoma
Interventions
MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS), MELITAC 12.1 + Montanide ISA-51 + polyICLC
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 24, 2026, 9:40 AM EDT
Active, not recruiting Phase 2 Interventional

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

NCT04114825
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
RV001V, Placebo
Biological · Other
Lead sponsor
RhoVac APS
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 24, 2026, 9:40 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

NCT01489956
View directory record Official record
Conditions
Autoimmune Disorders
Interventions
Immucothel Alone (Part A), Immucothel+Montanide (Part A), Immucothel Alone or Immucothel+Montanide (Part B)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 24, 2026, 9:40 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Vaccination With Tetanus and KLH to Assess Immune Responses.

NCT00000105
View directory record Official record
Conditions
Cancer
Interventions
Intracel KLH Vaccine, Biosyn KLH, Montanide ISA51, Tetanus toxoid
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

NCT00059475
View directory record Official record
Conditions
Melanoma
Interventions
Glycoprotein 100 (GP100): 209-217 (210M), Interleukin-2 (IL-2), Montanide ISA 51, Melanoma antigen recognized by T-cells (MART)-1: 27-35, 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1, melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

NCT00437502
View directory record Official record
Conditions
Epithelial Ovarian, Tubal or Peritoneal Cancer
Interventions
tumor peptide vaccine
Biological
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

NCT01673217
View directory record Official record
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions
decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride, sargramostim, incomplete Freund's adjuvant, immunohistochemistry staining method, liquid chromatography, mass spectrometry, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, DNA methylation analysis, enzyme-linked immunosorbent assay
Drug · Biological · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

NCT00109811
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 24, 2026, 9:40 AM EDT
Not listed Phase 2 Interventional

SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

NCT05163080
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma
Interventions
SurVaxM
Biological
Lead sponsor
MimiVax, LLC
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00003224
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
QS21, IFA (incomplete Freund's adjuvant), p946, p946/tet-p, Tet-p
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 24, 2026, 9:40 AM EDT
Terminated Phase 2 Interventional Results available

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

NCT00415857
View directory record Official record
Conditions
Leukemia
Interventions
Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib, GM-CSF
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

NCT00003274
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

NCT01079741
View directory record Official record
Conditions
Melanoma
Interventions
NY-ESO-1 protein; Poly-ICLC; Montanide
Biological
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

NCT00118274
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, cyclophosphamide
Biological · Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 120 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

NCT00003222
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tetanus peptide melanoma vaccine, tyrosinase peptide
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652
View directory record Official record
Conditions
Tumors
Interventions
NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 24, 2026, 9:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

NCT02425306
View directory record Official record
Conditions
Melanoma
Interventions
6MHP, Montanide ISA-51, polyICLC, Cyclophosphamide
Biological · Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

NCT01376505
View directory record Official record
Conditions
Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST, Ovarian Cancer
Interventions
HER-2 vaccine, Extension HER-2 vaccine trial at OBD
Biological
Lead sponsor
Robert Wesolowski
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

NCT03761914
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions
galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Biological · Other
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
12
States / cities
Santa Rosa, California • Whittier, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)

NCT03391232
View directory record Official record
Conditions
Colorectal Cancer
Interventions
PolyPEPI1018 CRC Vaccine
Biological
Lead sponsor
Treos Bio Zrt
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 24, 2026, 9:40 AM EDT
Completed Phase 2 Interventional

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00079144
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 peptide vaccine, aldesleukin, filgrastim, incomplete Freund's adjuvant, therapeutic autologous lymphocytes, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 24, 2026, 9:40 AM EDT
Active, not recruiting Phase 1 Interventional

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

NCT02334865
View directory record Official record
Conditions
Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
Interventions
Incomplete Freund's Adjuvant, Laboratory Biomarker Analysis, Lenalidomide, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 24, 2026, 9:40 AM EDT